Skip to main content
. 2019 Nov 22;22(4):539–549. doi: 10.1093/neuonc/noz185

Fig. 1.

Fig. 1

Trial design, enrollment, and survival. (A) Summary of trial schema. (B) Profile of the trial patient composition. LMD, leptomeningeal disease; cycle (c); and day (d). (C) PFS based on radiographic evidence of tumor recurrence in terms of gadolinium contrast enhancement seen on MRI. (D) OS.